SurVaxM is under clinical development by MimiVax and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM).

A personalised vaccine for the aggressive and fatal brain cancer glioblastoma has shown encouraging signs of efficacy in its first human trial. The vaccine – developed by researchers at the ...

ERC-1671 is under clinical development by ERC Belgium and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM).

Glioblastoma multiforme (GBM) is associated with a poor ... to assess the safety and immunogenicity of a dendritic cell-based vaccine targeting the EGFRvIII antigen. The study included patients ...

Fox News health commentator Dr. Kelly Powers was diagnosed with glioblastoma, an aggressive form of brain cancer, in July 2020, months before COVID-19 vaccines were made available in the U.S. But ...

"Russia has developed its own mRNA vaccine against cancer, it will be distributed to patients free of charge, General ...

People with glioblastoma who took part in the study lived more than twice as long as those on standard treatments in many cases, researchers say. The vaccine works by using the body's immune cells ...

The clinical effectiveness of personalized neoantigen-based vaccinations needs further research, although they have garnered a lot of interest in GBM vaccine treatment. In August 2024, a first-in ...